Search

Displaying results 5551 - 5560 of 6831 in total
  1. Drug

    Abrilumab

    go.drugbank.com/drugs/DB15076
    Investigational

    Abrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).

  2. Drug

    MOL-4239

    go.drugbank.com/drugs/DB16051
    Investigational

    MOL-4239 is under investigation in clinical trial NCT01826201 (Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis).

  3. Drug

    CEQ508

    go.drugbank.com/drugs/DB17911
    Experimental

    Coli Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.

  4. Drug

    Clesacostat

    go.drugbank.com/drugs/DB18956
    Investigational

    Clesacostat is under investigation in clinical trial NCT04321031 (Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)).

  5. Drug

    Efzofitimod

    go.drugbank.com/drugs/DB16453
    Investigational

    Efzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody.

  6. Drug

    TAS-102

    go.drugbank.com/drugs/DB08937
    Investigational

    Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trifluridine from being broken down when taken orally.

  7. Drug

    Seliciclib

    go.drugbank.com/drugs/DB06195
    Investigational

    Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation

  8. Drug

    Candoxatrilat

    go.drugbank.com/drugs/DB11623
    Experimental

    A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy

  9. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.

  10. Drug

    Enlonstobart

    go.drugbank.com/drugs/DB21890
    Investigational

    [A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.